Disruptive
behavior disorder
comprises a group of disorders including oppositional defiant
disorder, conduct disorder, and intermittent explosive disorder. It
usually affects young people below 18 years of age.
Children/teenagers suffering from this disorder are unable to
regulate her/his emotions and behaviors, act defiant, and are in
conflict with other peers in surrounding thereby facing low quality
of life at home, school, or both. Various causes of DBD include child
abuse or neglect, a traumatic life experience, such as sexual abuse
or violence, and a family history of DBDs. DBDs can be treated with
variety of option, initiated with psychological therapy. Under
psychological therapy, counselling and guidance is provided either to
parent or child alone, or family together, to improve response to
incidence of DBDs. Medication treatment is preferred either in
combination with psychological treatment or started when
psychological therapy proves to be insufficient.
Ask
for In-depth Sample Copy of This Research @
https://www.coherentmarketinsights.com/insight/request-sample/2390
Disruptive Behavior Disorder Medication Market - Market Dynamics
Major factors responsible for growth of the disruptive behavior
disorder medication market are rising burden of the disruptive
behavior disorders worldwide, increasing awareness amongst parent
about this disorder, and improvement of psychotic and medication
treatment. According to a study published in the journal BMJ Open
(Matthew D Burkey et al) in 2015, oppositional defiant disorder (ODD)
and conduct disorder (CD) had an estimated worldwide prevalence of
3.3% and 3.2%, respectively. World Health Organization in its 2016
factsheet stated that globally, 7.4 % of disability-adjusted life
years (DALYs) are caused by disorders in mental and behavioral
disorders category.
Disruptive Behavior Disorder Medication Market - Regional Insights
On the basis of geography, disruptive behavior disorder medication
market is segmented into North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa. North America is expected to be the
leading region in the disruptive behavior disorder medication market
during forecast period. According to statistics given by Agency for
Healthcare Research and Quality in 2016, 3 out of every 100 children
in the U.S. are affected by disruptive behavior disorder, it affects
more number of boys than girls and is common among children aged 12
years and older. ‘Speak Up for Kids’ campaign is an education and
outreach initiatives by Child Mind Institute (U.S. based non-profit
organization), through which awareness about mental health issues and
needed information is provided to families, educators, the media, and
policymakers. Various medical centers and hospitals such as Arkansas
Valley Behavioral Health System have established dedicated resources
for treatment of disruptive behavior disorder.
Disruptive Behavior Disorder Medication Market - Competitive
Landscape
Key players present in the disruptive behavior disorder medication
market are,
-
Promius Pharma LLC
-
Shire PLC
-
Johnson and Johnson
-
Mylan N.V.
-
Novartis AG
-
Teva Pharmaceuticals Industries Ltd.
-
GlaxoSmithKline plc
-
Sun Pharmaceutical Industries Ltd.
-
Lupin Ltd.
-
Eli Lilly and Company
Disruptive Behavior Disorder Medication Market - Market Taxonomy
On the basis of disease type, the global disruptive behavior
disorder medication market is segmented into: Oppositional Defiant
Disorder, Conduct Disorder, Intermittent Explosive Disorder
On the basis of drug class, the global disruptive behavior
disorder medication market is segmented into: Stimulant,
Antipsychotics, Alpha Agonist, Anticonvulsant, Others
On the basis of drug class, the global disruptive behavior
disorder medication market is segmented into: Hospital Pharmacy,
Retail Pharmacy, Online Pharmacy
On the basis of geography, the disruptive behavior disorder
medication market is segmented into: North America, Latin America,
Europe, Asia Pacific, Middle East, Africa
If
you have any special Requirement,
Talk to our analyst @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/2390
Also,
Coherent Market Insights has a proprietary database of pipeline
biologics and biosimilars, called PHASE-XS. This database provides
analytical data in addition to the clinical information of ongoing
trials for biologics and biosimilars. An amalgamation of more than 30
parameters, PHASE-XS helps biotechnology and pharmaceutical companies
to analyze the market trend, competition, and market potential. For
more information or to access this database, kindly click on the
below link or contact at sales@coherentmarketinsights.com
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment